Biotech Values

[rfj1862]

Results for the GLP-1/GIP agonist coming before end of Q12023. I was mostly thinking about this as a sideshow but analysts are weirdly excited about it?

One of the few PFE calls I listened to last year was dominated by analysts asking about their oral GLP-1 agonists (interestingly they had 2 they were progressing at the time one with more favorable pK amd the other slightly more advamced IIRC)
I think it’s just the sheer size of the commercial opportunity. Analysts are talking 15-25B in annual sales for LLY’s dual agonist and it can’t even be dosed orally

I'm going to have to think about this some more, I wasn't paying attention to Viking's dual agonist at all and wasn't accounting for it in my valuation projections. But clearly it is a big deal based on analyst excitement.

I mean I guess if all else fails and DD is right that MDGL's EPs won't be accepted by the FDA the company still has this to fall back on. Plus the Phase 2 trials for the dual agonist should be very easy and fast to enroll so they could have trials well underway.